Research

Hormonal

GLP-1 receptor agonists (semaglutide, tirzepatide) produce clinically significant weight loss (15-21%) and improve comorbidities, but require long-term continuous use to maintain benefits.

GLP-1 medications like semaglutide and tirzepatide are highly effective for significant weight loss (15-21%) and improving health conditions like diabetes and heart disease. However, they are not cosmetic shortcuts. You must commit to long-term use, as stopping the medication usually leads to regaining the weight. Work with your doctor to manage side effects and adjust other medications as you lose weight.

GoodSupportsHIGH confidence
individuals prescribed the drug semaglutide plus a lifestyle modification intervention for 68 weeks lost an average of 15% of their body weight... average weight loss at 72 weeks was 15%–21%... Maximum weight losses are reached after 12–18 months of continuous use for most individuals, with discontinuation being associated with weight regain for many.
Leah M. Schumacher et al. · Plastic & Reconstructive Surgery Global Open · 2025

Why this rating

Cites large-scale RCTs (STEP 1, SURMOUNT-1) and FDA approvals.

Source

Considerations for the Use of Glucagon-like Peptide-1 Medications for Obesity in a Plastic Surgery Setting

Leah M. Schumacher et al. · Plastic & Reconstructive Surgery Global Open · 2025

DOI 10.1097/gox.0000000000007085

narrative_reviewCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →